PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26920629-1 2016 AIMS: Memantine is a low-moderate affinity and uncompetitive N-methyl-d-aspartate receptor (NMDAR) antagonist, which is also a potential neuroprotectant in acute ischemic stroke for its particular action profiles. Memantine 6-15 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 61-90 26920629-1 2016 AIMS: Memantine is a low-moderate affinity and uncompetitive N-methyl-d-aspartate receptor (NMDAR) antagonist, which is also a potential neuroprotectant in acute ischemic stroke for its particular action profiles. Memantine 6-15 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 92-97 26609150-6 2015 We further validated these results pharmacologically by demonstrating similar reductions in the alcohol deprivation effect after infusion of the NMDAR antagonist memantine into the nucleus accumbens and ventral tegmental area of control mice, and a rescue of the mutant phenotype via pharmacological potentiation of AMPAR activity using aniracetam. Memantine 162-171 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 145-150 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 62-67 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 113-118 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 113-118 26089779-5 2015 Memantine, an NMDAR antagonist, was administered daily for 24 days to healthy adult CF-1 mice by oral gavage at doses of 5, 10, or 20 mg/kg. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 14-19 26301823-8 2015 When the NMDAR antagonist memantine was administered by intraperitoneal injection prior to daily exposure to CIH, at a sub-therapeutic dose of 5mg/kg/day not shown to impact the neurobehavioral performance in control animals, the neurocognitive impairments as well as the neurobiochemical changes were abolished or normalized in the CIH mice. Memantine 26-35 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 9-14 25974188-4 2015 Adolescent male mice were conditioned with 1 or 10 mg/kg MDMA and pretreated with 5 or 10 mg/kg of the NMDAR antagonist memantine during acquisition of conditioning (experiment 1), or before a reinstatement test (experiment 2). Memantine 120-129 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 103-108 26074764-4 2015 We report here that memantine, an NMDAR antagonist, administered to VPA mice rescues both social deficits and repetitive behaviors such as self-grooming and jumping. Memantine 20-29 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 25942563-4 2015 The aim of this study is to examine the effects of memantine, a NMDAR channel blocker, on bleomycin-induced lung injury mice. Memantine 51-60 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 64-69 25899790-3 2015 OBJECTIVES: The current experiments explore aggression and medial prefrontal cortex (mPFC) glutamate as consequences of withdrawal from intermittent access to EtOH and changes in aggression and mPFC glutamate caused by NMDAR antagonists memantine and ketamine. Memantine 237-246 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 219-224 26089779-11 2015 In conclusion, long-term NMDAR antagonism with memantine induces anxiety-like behavior that is associated with reduced glutamate uptake activity but that is not dependent on GLT-1 or GLAST protein expression. Memantine 47-56 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 25-30 24937439-12 2014 A single intraperitoneal dose of the NMDAr antagonists, memantine or MK-801, shortly before the intruder test decreased aggressive behavior. Memantine 56-65 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 37-42 24344200-2 2014 NMDAR antagonists are neuroprotective in animal models of neuronal diseases, and the NMDAR open-channel blocker memantine is used to treat Alzheimer"s disease. Memantine 112-121 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 85-90 24269729-5 2014 Chronic (2-month) treatment of YAC128 and WT mice with memantine (1 and 10mg/kg/day), which at a low dose selectively blocks Ex-NMDARs, reduced striatal Ex-NMDAR expression and current in 4-month old YAC128 mice without altering synaptic NMDAR levels. Memantine 55-64 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 128-133 24240127-5 2014 The NMDAR blockers MK-801 and memantine decreased mouse melanoma K1735-M2 cell proliferation. Memantine 30-39 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 21705496-6 2011 Using a murine model of HHcy (cbs(+/-)), treatment for 2 weeks with an NMDAr antagonist (memantine) rescued cerebrovascular expression of claudin-5 and blood-brain barrier permeability to both exogenous sodium fluorescein and endogenous IgG. Memantine 89-98 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 71-76 22668780-9 2012 Moreover, both NMDAR-mediated apoptosis and CREB-off signaling are blocked by co-application of either memantine or the GluN2B subunit-selective antagonist ifenprodil in YAC128 MSNs. Memantine 103-112 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 15-20 22119002-3 2012 BsHSPMG inhibited the activity of NR1/NR2A and NR1/NR2B receptors more strongly and did it for those of NR1/NR2C and NR1/NR2D receptors more weakly than a therapeutic drug of Alzheimer"s disease, memantine. Memantine 196-205 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-37 19361551-9 2009 ERK activation could indicate a stress-mediated increase in glutamatergic signaling, therefore mice were treated prior to SNI and stress with memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 156-185 20577261-4 2011 Sustained calcium (Ca(2+)) signals and caspase-3 activation in thymocytes were induced by interaction with antigen-pulsed dendritic cells (DCs) and were inhibited by NMDAR antagonists MK801 and memantine. Memantine 194-203 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 166-171 19915593-7 2009 By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-84 19361551-9 2009 ERK activation could indicate a stress-mediated increase in glutamatergic signaling, therefore mice were treated prior to SNI and stress with memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 187-192 18843265-5 2009 Results showed that one N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, but not another, dextromethorphan, potentiated the ataxic but not hypothermic or sedative/hypnotic effects of ethanol. Memantine 74-83 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 24-53 18843265-5 2009 Results showed that one N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, but not another, dextromethorphan, potentiated the ataxic but not hypothermic or sedative/hypnotic effects of ethanol. Memantine 74-83 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 55-60 18486118-2 2008 We tested the hypothesis that uncompetitive NMDAR blockade with memantine prevents mitochondrial dysfunction-related neurodegeneration in vivo, using a mouse model of retinal ganglion cell layer (GCL) degeneration induced by rotenone, a mitochondrial complex I inhibitor. Memantine 64-73 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 44-49 19154422-5 2009 We assessed the effects of truncating [at residue Iso1098; NR2A(trunC)] and deleting [from residue Phe822; NR2A(delC)] the CTD of NR2A NMDAR subunits on agonist potencies, channel block by Mg(2+) and memantine and potentiation of NMDAR-mediated responses by chelating contaminating divalent cations. Memantine 200-209 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 135-140 18828800-5 2008 An exception is the moderate affinity NMDAR channel blocker memantine, used in Alzheimer"s dementia. Memantine 60-69 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 38-43 17700645-7 2008 of the uncompetitive NMDAR antagonist memantine rescue performance deficits of Ts65Dn mice on a fear conditioning test. Memantine 38-47 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 21-26 17700645-8 2008 Because the actions of memantine on NMDAR kinetics had been shown by others to mimic somewhat the actions of calcineurin, we attributed this positive effect of memantine on Ts65Dn mice to a drug-mediated "normalization" of NMDAR function. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 36-41 16859831-2 2006 NMDAR antagonists, including MK-801 and memantine, have previously been shown to assuage symptoms stemming from opiate withdrawal. Memantine 40-49 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 0-5 8886398-12 1996 The kinetics of the actions of memantine (30 microM) were investigated for the NR1a/2A combination, in 6 cells (13-15 determinations). Memantine 31-40 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-82 34131204-10 2021 Lastly, treatment with memantine (NMDAR antagonist) at 4 and 24 h after stroke significantly reduced gliosis at PSD14. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 34646371-7 2021 The N-methyl-D-aspartate receptor (NMDAR) antagonist memantine was used to treat the KO mice for rescuing the phenotypes. Memantine 53-62 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-33 34646371-7 2021 The N-methyl-D-aspartate receptor (NMDAR) antagonist memantine was used to treat the KO mice for rescuing the phenotypes. Memantine 53-62 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 35-40 34646371-13 2021 The NMDAR antagonist memantine could rescue GABAergic transmission in the hippocampus and ameliorate autistic-like behaviors of the KO mice. Memantine 21-30 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 32860269-5 2020 Furthermore, the NMDAR antagonist memantine can relieve the stress-induced depression-like behaviors of FGR mice. Memantine 34-43 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 17-22 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 16-46 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 48-53 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 66-71 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 107-112 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 184-189 33882517-5 2021 In this study, we demonstrate that memantine, a N-methyl-D-aspartic acid receptor (NMDAR) antagonist, through suppressing Ca2+ influx and subsequent ASC oligomerization inhibits macrophage Nlrp3 inflammasome activation and pyroptosis, therefore, alleviates ALI in septic mice. Memantine 35-44 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 83-88 35453065-1 2022 Currently, of the few accessible symptomatic therapies for Alzheimer"s disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. Memantine 85-94 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 138-143 35453065-4 2022 Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. Memantine 177-186 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 157-162 33915770-10 2021 Memantine alleviated pain indicators in diabetic mice and suppressed excessive NMDAR1 activation, glutamate, and pro-inflammatory cytokine release in the spinal cord. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-85 31308798-1 2019 Memantine is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist clinically approved for moderate-to-severe Alzheimer"s disease (AD) to improve cognitive functions. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 31-60 33500723-8 2021 The NMDAR blockade by Memantine decreased the susceptibility to insulin resistance and hepatic steatosis in obese mice. Memantine 22-31 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 31682950-3 2019 We have previously shown that the NMDAR antagonist memantine lessens axonal injury and restores long term potentiation after rmTBI. Memantine 51-60 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 31308798-1 2019 Memantine is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist clinically approved for moderate-to-severe Alzheimer"s disease (AD) to improve cognitive functions. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 62-67 27423317-8 2016 We used different stimuli such as NMDA and glutamate, LPS and TNFalpha in combination with NMDA-R antagonism using memantine and MK801 in astrocytic cell culture. Memantine 115-124 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 91-97 30845688-4 2019 Memantine is an N-methyl-D-aspartate receptor (NMDAR) antagonist commonly used to treat Alzheimer"s disease. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 16-45 30845688-4 2019 Memantine is an N-methyl-D-aspartate receptor (NMDAR) antagonist commonly used to treat Alzheimer"s disease. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 47-52 30293574-6 2018 NMDAR antagonists also blocked the activation of calcium-calmodulin-dependent protein kinase II and treatment of Tg2576 AD model mice with the NMDAR antagonist, memantine, prevented CCR. Memantine 161-170 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 0-5 30293574-6 2018 NMDAR antagonists also blocked the activation of calcium-calmodulin-dependent protein kinase II and treatment of Tg2576 AD model mice with the NMDAR antagonist, memantine, prevented CCR. Memantine 161-170 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 143-148 28303894-9 2017 Furthermore, another NMDAR antagonist, Memantine, improved beta-cells function in diabetic mice. Memantine 39-48 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 21-26 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 33-38 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 60-65 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 60-65 29913137-6 2018 Memantine, a selective NMDAR antagonist, improved prenatal CTM-induced abnormal protein levels and social interaction deficits. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 23-28 28412305-9 2018 Treatment with memantine also corresponded to normal NMDAR expression after rmTBI. Memantine 15-24 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 53-58 29112047-2 2017 Memantine, a noncompetitive N-methyl-D-aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active cardioprotective drug. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 28-71 29112047-2 2017 Memantine, a noncompetitive N-methyl-D-aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active cardioprotective drug. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 73-79